These nonclinical and interim clinical data are exploratory and do not constitute a regulatory or commercial catalyst. Monitor for topline Phase 2 CAReS results and any subsequent partnership or financing needs given the small market cap.
Price Chart
Executive Summary
Artelo Biosciences announced nonclinical results showing ART27.13 reduced neuropathic pain behaviors in a paclitaxel-induced peripheral neuropathy model, alongside interim Phase 2 CAReS data showing positive trends in body weight, lean body mass, and activity for CACS patients. As a $4M market-cap clinical-stage biotech with no approved products or revenue, these are early-stage scientific findings that do not change the company's fundamental risk profile.
Key Facts
- Nonclinical study: ART27.13 reduced mechanical allodynia and thermal hyperalgesia in paclitaxel-treated animals, suggesting potential for chemotherapy-induced peripheral neuropathy
- Interim CAReS Phase 2 data: top dose showed mean weight gain >6% vs 5% loss on placebo; improvements in lean body mass and activity levels
- No FDA-approved treatments exist for CACS, representing an unmet medical need
- ART27.13 is peripherally restricted to avoid CNS side effects; originally developed by AstraZeneca
- CAReS is a Phase 1/2 randomized, placebo-controlled trial; interim data is blinded and not yet finalized
Financial Impact
No revenue, no profitability, no financial metrics disclosed; $4M market cap
Risk Factors
- Nonclinical results may not translate to human clinical outcomes
- ART27.13 is in Phase 2 with no approved products; clinical failure risk is high
- No revenue or near-term commercialization pathway disclosed
- Micro-cap with $4M market cap faces financing/dilution risk to continue development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3326230 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 17d ago | 8-K | $3.11 | awaiting T+60 | — | $2.14 (+31.19%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.14 (−42.93%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.14 (−68.67%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.14 (+87.72%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.14 (+87.72%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.14 (+103.81%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.14 (−92.79%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.14 (−46.58%) |
May 18, 2026 23w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.14 (+57.35%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.14 (+46.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers